{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:55:35Z","timestamp":1792713335803,"version":"4.5.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder affecting motile cilia, leading to impaired mucociliary clearance and increased susceptibility to respiratory infections. These infections contribute to long-term complications such as bronchiectasis and lung function decline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This review explores both the acute and long-term impact of respiratory infections in children with PCD, while highlighting the multiple contributors to infection susceptibility. The review also evaluates emerging personalized approaches such as gene and mRNA therapy that hold promise for restoring ciliary function and reducing the burden of acute infections in pediatric PCD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key findings and conclusions<\/jats:title><jats:p>Acute respiratory infections have a significant impact on morbidity in pediatric PCD, driving progressive airway remodeling. While current treatment strategies focus on managing infections directly, emerging therapies targeting inflammation and genetic causes hold promise for reducing infection burden and improving long-term outcomes. Future advances in personalized medicine could further enhance therapeutic approaches in this population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1564156","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:02:20Z","timestamp":1742281340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Beyond the present: current and future perspectives on the role of infections in pediatric PCD"],"prefix":"10.3389","volume":"13","author":[{"given":"Megan","family":"Frohlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Prentice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafagh","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/ppul.23304","article-title":"Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review","volume":"51","author":"Shapiro","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9834","DOI":"10.3390\/ijms22189834","article-title":"Current and future treatments in primary ciliary dyskinesia","volume":"22","author":"Paff","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1183\/13993003.00736-2016","article-title":"Clinical manifestations in primary ciliary dyskinesia: systematic review and meta-analysis","volume":"48","author":"Goutaki","year":"2016","journal-title":"Eur Respir J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1378\/chest.11-0679","article-title":"The burden of disease in pediatric non-cystic fibrosis bronchiectasis","volume":"141","author":"Kapur","year":"2012","journal-title":"Chest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/ppul.23479","article-title":"Recovery of baseline lung function after pulmonary exacerbation in children with primary ciliary dyskinesia","volume":"51","author":"Sunther","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1164\/rccm.200303-365OC","article-title":"Primary ciliary dyskinesia: diagnostic and phenotypic features","volume":"169","author":"Noone","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1093 e1","DOI":"10.1016\/j.cmi.2015.08.020","article-title":"A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia","volume":"21","author":"Alanin","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"B8","doi-asserted-by":"publisher","first-page":"00147-2018","DOI":"10.1183\/23120541.00147-2018","article-title":"Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials","volume":"5","author":"Lucas","year":"2019","journal-title":"ERJ Open Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1183\/09031936.00176608","article-title":"Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children","volume":"34","author":"Barbato","year":"2009","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1101\/2025.01.13.25320478","article-title":"Incidence and predictors of pulmonary exacerbations in primary ciliary dyskinesia: an international prospective cohort study","author":"Schreck","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12887-020-02062-4","article-title":"Exacerbations and Pseudomonas aeruginosa colonization are associated with altered lung structure and function in primary ciliary dyskinesia","volume":"20","author":"Piatti","year":"2020","journal-title":"BMC Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"00218-2024","DOI":"10.1183\/23120541.00218-2024","article-title":"Definition of sinonasal and otological exacerbation in patients with primary ciliary dyskinesia: an expert consensus","volume":"10","author":"Goutaki","year":"2024","journal-title":"ERJ Open Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/archdischild-2013-305147","article-title":"Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children","volume":"99","author":"Kapur","year":"2014","journal-title":"Arch Dis Child"},{"key":"B14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1164\/rccm.201409-1672OC","article-title":"Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype","volume":"191","author":"Davis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/ppul.22984","article-title":"Multicenter analysis of body mass index, lung function, and sputum microbiology in primary ciliary dyskinesia","volume":"49","author":"Maglione","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1038\/s41467-021-24521-x","article-title":"SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance","volume":"12","author":"Robinot","year":"2021","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1128\/iai.61.7.2848-2853.1993","article-title":"Mechanisms of action of Pseudomonas aeruginosa pyocyanin on human ciliary beat in vitro","volume":"61","author":"Kanthakumar","year":"1993","journal-title":"Infect Immun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1183\/13993003.00209-2016","article-title":"A longitudinal study characterising a large adult primary ciliary dyskinesia population","volume":"48","author":"Shah","year":"2016","journal-title":"Eur Respir J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1378\/chest.09-2932","article-title":"Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?","volume":"138","author":"Kapur","year":"2010","journal-title":"Chest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12890-021-01762-6","article-title":"Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study","volume":"21","author":"Lim","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1183\/13993003.01390-2015","article-title":"Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia","volume":"47","author":"Ratjen","year":"2016","journal-title":"Eur Respir J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1710-1492-2-3-98","article-title":"Mechanisms of degranulation in neutrophils","volume":"2","author":"Lacy","year":"2006","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"230234","DOI":"10.1183\/16000617.0234-2023","article-title":"Biomarkers in bronchiectasis","volume":"33","author":"Johnson","year":"2024","journal-title":"Eur Respir Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"317S","DOI":"10.1378\/chest.117.5_suppl_1.317S","article-title":"Neutrophil elastase induces MUC5AC messenger RNA expression by an oxidant-dependent mechanism","volume":"117","author":"Fischer","year":"2000","journal-title":"Chest"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15874","DOI":"10.1038\/s41598-020-72667-3","article-title":"Neutrophil elastase promotes macrophage cell adhesion and cytokine production through the integrin-Src kinases pathway","volume":"10","author":"Krotova","year":"2020","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","article-title":"Physiology and pathophysiology of human airway mucus","volume":"102","author":"Hill","year":"2022","journal-title":"Physiol Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"eabo7728","DOI":"10.1126\/scitranslmed.abo7728","article-title":"Chronic airway epithelial hypoxia exacerbates injury in muco-obstructive lung disease through mucus hyperconcentration","volume":"15","author":"Mikami","year":"2023","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMra1813799","article-title":"Muco-obstructive lung diseases","volume":"380","author":"Boucher","year":"2019","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.chest.2019.10.023","article-title":"Ventilation inhomogeneity and bronchial basement membrane changes in chronic neutrophilic airway inflammation","volume":"157","author":"Kouck\u00fd","year":"2020","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/thx.2006.074641","article-title":"Airway remodelling in children with cystic fibrosis","volume":"62","author":"Hilliard","year":"2007","journal-title":"Thorax"},{"key":"B32","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1164\/rccm.200707-977OC","article-title":"Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis","volume":"177","author":"Regamey","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1513\/AnnalsATS.202204-314OC","article-title":"Airway inflammation in children with primary ciliary dyskinesia","volume":"20","author":"Sagel","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"102428","DOI":"10.1016\/j.mib.2024.102428","article-title":"Insights into the role of the respiratory tract microbiome in defense against bacterial pneumonia","volume":"77","author":"Drigot","year":"2024","journal-title":"Curr Opin Microbiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41467-017-01803-x","article-title":"The microbiota protects against respiratory infection via GM-CSF signaling","volume":"8","author":"Brown","year":"2017","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/infdis\/jiu326","article-title":"High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia","volume":"210","author":"Wolter","year":"2014","journal-title":"J Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1004923","DOI":"10.1371\/journal.ppat.1004923","article-title":"The lung microbiome: new principles for respiratory bacteriology in health and disease","volume":"11","author":"Dickson","year":"2015","journal-title":"PLoS Pathog"},{"key":"B38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0140-6736(14)61136-3","article-title":"The role of the microbiome in exacerbations of chronic lung diseases","volume":"384","author":"Dickson","year":"2014","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1128\/JCM.02164-13","article-title":"Complexity, temporal stability, and clinical correlates of airway bacterial community composition in primary ciliary dyskinesia","volume":"51","author":"Rogers","year":"2013","journal-title":"J Clin Microbiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41392-023-01722-y","article-title":"Lung microbiome: new insights into the pathogenesis of respiratory diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.rmed.2017.08.028","article-title":"Clinical impact of Pseudomonas aeruginosa colonization in patients with primary ciliary dyskinesia","volume":"131","author":"Cohen-Cymberknoh","year":"2017","journal-title":"Respir Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1513\/AnnalsATS.202404-340OC","article-title":"Long-term lung function and Pseudomonas aeruginosa infection in genotyped primary ciliary dyskinesia","volume":"22","author":"Holgersen","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"B43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ppul.26816","article-title":"The airway microbiota in siblings with primary ciliary dyskinesia: related factors and correlation with clinical characteristics","volume":"59","author":"Ademhan Tural","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"00301","DOI":"10.1183\/23120541.00301-2021","article-title":"International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD core network and patient representatives","volume":"7","author":"Marthin","year":"2021","journal-title":"ERJ Open Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"CD006682","DOI":"10.1002\/14651858.CD006682.pub6","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","volume":"9","author":"Abbott","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/resp.14479","article-title":"Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand","volume":"28","author":"Chang","year":"2023","journal-title":"Respirology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"B48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.prrv.2015.10.002","article-title":"Treatment recommendations in Primary Ciliary Dyskinesia","volume":"18","author":"Polineni","year":"2016","journal-title":"Paediatr Respir Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2002990","DOI":"10.1183\/13993003.02990-2020","article-title":"European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis","volume":"58","author":"Chang","year":"2021","journal-title":"Eur Respir J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1901472","DOI":"10.1183\/13993003.01472-2019","article-title":"Primary ciliary dyskinesia patients have the same P. aeruginosa clone in sinuses and lungs","volume":"55","author":"Arndal","year":"2020","journal-title":"Eur Respir J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1513\/AnnalsATS.202210-858OC","article-title":"Efficacy of antibiotic eradication therapy of early Pseudomonas aeruginosa infection in children with primary ciliary dyskinesia","volume":"20","author":"Gatt","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1479972318787919","DOI":"10.1177\/1479972318787919","article-title":"Variation in treatment strategies for the eradication of Pseudomonas aeruginosa in primary ciliary dyskinesia across European centers","volume":"16","author":"Crowley","year":"2019","journal-title":"Chron Respir Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.prrv.2017.03.011","article-title":"Airway clearance techniques for Primary Ciliary Dyskinesia; is the Cystic Fibrosis literature portable?","volume":"25","author":"Schofield","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"B54","first-page":"71","article-title":"Physiotherapy English national standards of care for children with primary ciliary dyskinesia","volume":"50","author":"Schofield","year":"2018","journal-title":"J ACPRC"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1183\/09031936.98.11061389","article-title":"Airway response of children with primary ciliary dyskinesia to exercise and beta2-agonist challenge","volume":"11","author":"Phillips","year":"1998","journal-title":"Eur Respir J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ppul.22861","article-title":"Comparison of conventional pulmonary rehabilitation and high-frequency chest wall oscillation in primary ciliary dyskinesia","volume":"49","author":"Gokdemir","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"858410","DOI":"10.3389\/fped.2022.858410","article-title":"The short term influence of chest physiotherapy on lung function parameters in children with cystic fibrosis and primary ciliary dyskinesia","volume":"10","author":"Vandervoort","year":"2022","journal-title":"Front Pediatr"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1002\/ppul.25099","article-title":"Comparison of conventional chest physiotherapy and oscillatory positive expiratory pressure therapy in primary ciliary dyskinesia","volume":"55","author":"Bingol","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e27412","DOI":"10.1002\/ppul.27412","article-title":"Therapies used by children with primary ciliary dyskinesia: a natural history study","volume":"60","author":"Gardner","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1753466619866102","DOI":"10.1177\/1753466619866102","article-title":"Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review","volume":"13","author":"Maiz Carro","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1601770","DOI":"10.1183\/13993003.01770-2016","article-title":"A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia","volume":"49","author":"Paff","year":"2017","journal-title":"Eur Respir J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ppul.25206","article-title":"Effectiveness of hypertonic saline nebulization in airway clearance in children with non-cystic fibrosis bronchiectasis: a randomized control trial","volume":"56","author":"Anuradha","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase study group","volume":"113","author":"O'Donnell","year":"1998","journal-title":"Chest"},{"key":"B64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ppul.1950200509","article-title":"Clinical benefit from nebulized human recombinant DNase in Kartagener\u2019s syndrome","volume":"20","author":"Desai","year":"1995","journal-title":"Pediatr Pulmonol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.rmed.2007.05.014","article-title":"Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia","volume":"101","author":"El-Abiad","year":"2007","journal-title":"Respir Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/(SICI)1099-0496(199901)27:1%3C59::AID-PPUL11%3E3.0.CO;2-D","article-title":"DNase treatment in primary ciliary dyskinesia\u2013assessment by nocturnal pulse oximetry","volume":"27","author":"ten Berge","year":"1999","journal-title":"Pediatr Pulmonol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1164\/rccm.201301-0059CI","article-title":"Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease","volume":"188","author":"Knowles","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"Cd012406","DOI":"10.1002\/14651858.CD012406.pub2","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B69","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2213-2600(20)30058-8","article-title":"Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial","volume":"8","author":"Kobbernagel","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"14453","DOI":"10.1038\/s41598-023-41577-5","article-title":"Azithromycin promotes proliferation, and inhibits inflammation in nasal epithelial cells in primary ciliary dyskinesia","volume":"13","author":"Varenyiova","year":"2023","journal-title":"Sci Rep"},{"key":"B71","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S2213-2600(23)00226-6","article-title":"Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial","volume":"12","author":"Ringshausen","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.93.01020161","article-title":"The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia","volume":"1","author":"Stafanger","year":"1988","journal-title":"Eur Respir J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e001236","DOI":"10.1136\/bmjresp-2022-001236","article-title":"Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and\/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2\u2009\u00d7\u20092 partial factorial, randomised controlled trial","volume":"9","author":"Chang","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"8486","DOI":"10.1074\/jbc.M115.707109","article-title":"Neutrophilic cathepsin C is maturated by a multistep proteolytic process and secreted by activated cells during inflammatory lung diseases","volume":"291","author":"Hamon","year":"2016","journal-title":"J Biol Chem"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"00151","DOI":"10.1183\/23120541.00151-2024","article-title":"Brensocatib in non\u2013cystic fibrosis bronchiectasis: ASPEN protocol\/baseline characteristics","volume":"10","author":"Chalmers","year":"2024","journal-title":"ERJ Open Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"00633","DOI":"10.1183\/23120541.00633-2022","article-title":"A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf","volume":"9","author":"Chalmers","year":"2023","journal-title":"ERJ Open Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e1000422","DOI":"10.1371\/journal.pgen.1000422","article-title":"Ciliary beating recovery in deficient human airway epithelial cells after lentivirus ex vivo gene therapy","volume":"5","author":"Chhin","year":"2009","journal-title":"PLoS Genet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/gt.2013.79","article-title":"Restoring ciliary function to differentiated primary ciliary dyskinesia cells with a lentiviral vector","volume":"21","author":"Ostrowski","year":"2014","journal-title":"Gene Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/jmedgenet-2015-103539","article-title":"Gene editing of DNAH11 restores normal cilia motility in primary ciliary dyskinesia","volume":"53","author":"Lai","year":"2016","journal-title":"J Med Genet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.pupt.2022.102134","article-title":"Inhaled delivery of a lipid nanoparticle encapsulated messenger RNA encoding a ciliary protein for the treatment of primary ciliary dyskinesia","volume":"75","author":"Woo","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"key":"B83","article-title":"Rescue of Ciliary Function in Cell-Based Primary Ciliary Dyskinesia Models Using Nebulized, Lipid Nanoparticle (LNP)-Formulated mRNA","author":"Hennig","year":""},{"key":"B84","article-title":"ETHRIS Pipeline (2024)","author":"Rudolph","year":""},{"key":"B85","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am J Hum Genet"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"L231","DOI":"10.1152\/ajplung.90209.2008","article-title":"Ciliated epithelial cell lifespan in the mouse trachea and lung","volume":"295","author":"Rawlins","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/hum.2023.102","article-title":"Restoring ciliary function: gene therapeutics for primary ciliary dyskinesia","volume":"34","author":"Keiser","year":"2023","journal-title":"Hum Gene Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.jcf.2017.09.005","article-title":"Recent progress in translational cystic fibrosis research using precision medicine strategies","volume":"17","author":"Cholon","year":"2018","journal-title":"J Cyst Fibros"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2000455","DOI":"10.1183\/13993003.00455-2020","article-title":"Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia","volume":"58","author":"Lee","year":"2021","journal-title":"Eur Respir J"},{"key":"B93","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.201311-2047OC","article-title":"Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype","volume":"189","author":"Knowles","year":"2014","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1564156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:02:26Z","timestamp":1742281346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1564156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":93,"alternative-id":["10.3389\/fped.2025.1564156"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1564156","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"article-number":"1564156"}}